Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Mon, 13.12.2021
Aspermont Limited
Preliminary FY2021 shows positive Net Profit After Tax
FY2021 preliminary report shows continued growth
As per their preliminary numbers, the company has delivered on all their
guidance:
- Overall growth
- Subscriptions growth rate to go back to pre-Covid-19 levels
- Growth in audience
- High growth in new products
- Continue [ … ]
Fri, 10.12.2021
HAEMATO AG
In operational terms, HAEMATO AG is heading for a record year following the
acquisition of M1 Aesthetics GmbH. In addition, the expansion of their
private label business is increasingly coming into focus. In this regard,
the company plans to expand its portfolio with a botulinum toxin product
under its own brand. GBC analyst Cosmin Filker spoke wi [ … ]
Thu, 09.12.2021
EasyMotionSkin Tec AG
Successful listing of EasyMotionSkin Tec AG on the m:access of the Munich
Stock Exchange
On 09.12.2021 EasyMotionSkin Tec AG was successfully listed on the m:access
of the Munich Stock Exchange. The initial share price is 14.50 EUR.
According to the management, no extensive capital market transactions are
planned in the near future.
The EasyMo [ … ]
Thu, 09.12.2021
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 50,00.
Zusammenfassung:
Haemato hat Q3-Kennzahlen gemeldet, die eine anhaltend gute
Geschäftsdynamik zeigten, angeführt von einem [ … ]
Mon, 06.12.2021
PSI AG
First Berlin Equity Research hat ein Research Update zu PSI AG (ISIN:
DE000A0Z1JH9) veröffentlicht. Analyst Simon Scholes bestätigt seine
ADD-Empfehlung und erhöht das Kursziel von EUR 33,00 auf EUR 49,00.
Zusammenfassung:
Die Parteien der neuen deutschen Regierung (SPD, Grüne und Freie
Demokraten) haben sich darauf geeinigt, [ … ]
Mon, 06.12.2021
Defence Therapeutics Inc.
'We can work on any disease and adapt to any emergent pandemic such as the
one related to SARS-CoV2'
In its current letter to shareholders, Defence Therapeutics reports the
successful completion of its protein-based COVID vaccine (AccuVAC-PT001)
toxicology studies in non-rodent rabbit model. The AccuVAC-PT001 vaccine is
an injectable vaccine cap [ … ]
Thu, 02.12.2021
M1 Kliniken AG
First Berlin Equity Research hat am 02.12.2021 die Coverage von M1 Kliniken
AG (ISIN: DE000A0STSQ8/ Bloomberg: M12 GR) wieder aufgenommen. Analyst
Ellis Acklin stuft die Aktie mit einem Buy-Rating ein, bei einem Kursziel
von EUR 14,00.
Zusammenfassung:
Wir nehmen die Coverage der M1 Kliniken AG (M1) mit einem Buy-Rating und
einem Kursziel von &e [ … ]
Thu, 25.11.2021
Aroundtown SA
First Berlin Equity Research hat ein Research Update zu Aroundtown SA
(ISIN: LU1673108939) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 8,60.
Zusammenfassung:
Der Q3-Bericht lag nahe an unseren Zielen und war von der laufenden
Veräußerung von nicht zum Kerngesch [ … ]
Wed, 24.11.2021
Diversified Energy PLC
First Berlin Equity Research has published a research update on Diversified
Energy PLC (ISIN: GB00BYX7JT74). Analyst Simon Scholes reiterated his BUY
rating and maintained his GBp 150.00 price target.
Abstract:
At its Capital Markets Day on 17 November, DEC announced additional
investments in methane reduction initiatives and equipment. By 2026, [ … ]
Mon, 22.11.2021
IGEA Pharma N.V.
Reverse IPO of Blue Sky Natural Resources in IGEA Pharma. Realignment to
CBD extraction. Aggressive growth expected with strong scaling effects.
Blue Sky Natural Resources Ltd. (Blue Sky) was contributed to IGEA Pharma
N.V. (IGEA Pharma) on 27 September 2021 via a capital increase in kind. The
business model is now to change fundamentally. The w [ … ]